Simcere: China clears rheumatoid arthritis drug
Chinese drugmaker Simcere Pharmaceutical Group said Thursday that its rheumatoid arthritis drug Iremod received marketing approval from China's State Food and Drug Administration.
Iremod is intended to treat active rheumatoid arthritis. Simcere's other products include the cancer treatments Endu and Sinofuan, along with branded generic drugs and over-the-counter products.
American depositary shares of Simcere rose 9 cents to $8.60 in afternoon trading.
